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S U M M A R Y
It is well known that statins may cause elevation of liver enzymes, but the association of statins with
hepatitis B reactivation has never been reported before. A case of hepatitis B reactivation induced by
atorvastatin is reported herein. Atorvastatin not only caused signiﬁcant increases in aminotransferases,
but also caused ongoing viral replication by evidence of a several-log increase in hepatitis B virus. The
reactivation recovered spontaneously by discontinuation of atorvastatin. The evolving concept of a
double-edged sword with regard to statins in patients with hepatitis B is discussed.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Statins are widely used drugs that interfere with cholesterol
synthesis. Aggressive statin therapy has led to a great reduction in
cardiac events. Although, statins are potentially hepatotoxic drugs
and can cause elevations in aminotransferases, to our knowledge
the association between hepatitis B virus (HBV) reactivation and
statin use has not been reported before. A case of atorvastatin
causing hepatitis B reactivation associated with signiﬁcant
elevation of both aminotransferases and hepatitis B viral load is
reported.
2. Case report
In August 2010, a 48-year-old male had chest pains and was
diagnosed with an acute myocardial infarction. He underwent
placement of a left anterior descending coronary artery stent. He
was noncompliant with the free sample medication rosuvastatin.
He came to our clinic in February 2012 and was found to have low-
density lipoprotein (LDL) of 177 mg/dl, was hepatitis B surface
antigen-positive, had HBV DNA of 3.3 log10 IU/ml, was hepatitis B
‘e’ antibody-positive, and hepatitis C virus antibody-negative;
alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) were 41 and 29 IU/l, respectively. A liver ultrasound showed
coarse and heterogeneous echotexture, but liver magnetic* Tel.: +1 212 379 6996; fax: +1 212 379 6930.
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http://dx.doi.org/10.1016/j.ijid.2013.04.001resonance imaging ruled out cirrhosis. He had a good response
to atorvastatin 40 mg taken daily. Three months later, his LDL had
decreased to 78 mg/dl (Figure 1A), ALT/AST had slightly increased
to 48/34 IU/l (Figure 1B), and HBV DNA had slightly increased to
3.82 log10 IU/l (Figure 1C). After 8 months of atorvastatin
treatment, ALT/AST had jumped to 322/120 IU/l, and HBV DNA
had increased to 6.85 log10 IU/l. He remained asymptomatic and a
liver ultrasound was unchanged. Atorvastatin was discontinued.
The anti-virus agent tenofovir was prescribed, but he never took it.
His liver function and hepatitis B viral load had improved at the 1-
month follow-up visit, and the elevated levels rapidly declined to
near baseline at 2 months after the discontinuation of atorvastatin
(Figure 1). However LDL was increased to 185 mg/dl. A low dose of
simvastatin 10 mg daily was given. His liver function and DNA
continued to improve to baseline values (Figure 1).
3. Discussion
Statins are one of the most commonly prescribed medications
in the world. Statins block the cholesterol synthesizing pathway in
the liver. The World Health Organization reported that two billion
people worldwide have been infected with HBV. These facts
suggest the possibility of a strong relationship between statin use
and hepatitis B, but there are only a few reports of an interaction
between hepatitis B and statins. Recent studies have shown that
statins not only potentiate anti-HBV activity,1 but may also reduce
the risk of hepatocellular carcinoma in patients with hepatitis B.2
Authors have also indicated that the protective effects should be
interpreted with caution given the possibility of residualses. Published by Elsevier Ltd. All rights reserved.
Figure 1. (A) LDL level. (B) ALT/AST level. (C) Hepatitis B virus load.
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HBV infection. Statins are well-recognized immunomodulators.
Statins induce the accumulation of regulatory T cells (Tregs).3 This
proliferation is harmful to those patients with an HBV infection. Ameta-analysis showed patients with HBV infection to have higher
Tregs than the normal population.4 A higher HBV load is
accompanied by higher Tregs. So statins might impair antiviral
immune responses by increasing Tregs. From the evidence above, it
is a reasonable hypothesis that statins may cause hepatitis B
reactivation through a regulatory T cell pathway. Hepatitis B
reactivation has been widely reported in patients who have
undergone chemotherapy,5 but there is no report that hepatitis B
reactivation is related to statins. This case clearly showed that
chronic hepatitis B was reactivated by atorvastatin 40 mg taken
daily, with evidence of signiﬁcant increases in viral load and liver
enzymes, and this reactivation was reversed by discontinuation of
atorvastatin (Figure 1). Statins may not only cause simple
elevations in liver enzymes, but may also cause more serious
consequences, such as hepatitis B reactivation. An elevation of liver
enzymes in patients with hepatitis B who are being treated with
statins may need further investigation for possible hepatitis B
reactivation.
In conclusion, vigilance is required for patients with hepatitis B
infection who need high-dose statins.
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